Nuvectis Pharma
NVCT
11 hedge funds and large institutions have $7.2M invested in Nuvectis Pharma in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
55% more capital invested
Capital invested by funds: $4.65M → $7.2M (+$2.55M)
38% more funds holding
Funds holding: 8 → 11 (+3)
0.12% more ownership
Funds ownership: 4.94% → 5.06% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$1.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$434K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$288K |
| 4 |
State Street
Boston,
Massachusetts
|
+$145K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RC
Ronit Capital
London,
United Kingdom
|
-$1.62M |
| 2 |
Millennium Management
New York
|
-$312K |
| 3 |
VF
Virtu Financial
New York
|
-$84K |
| 4 |
BlackRock
New York
|
-$8.33K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.82K |
NVCT Hedge Fund Activity: Q2 2022 in Review
11 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q2 2022, worth a combined $7.2M — up 55% from $4.65M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NVCT positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Baldwin Wealth Partners, opening a new position worth an estimated $1.5M. The largest seller was Ronit Capital, cutting an estimated $1.62M.
- 11 institutional investors held Nuvectis Pharma (NVCT) as of Q2 2022, up from 8 in Q1 2022.
- Funds reported $7.2M of Nuvectis Pharma stock for Q2 2022, up 55% quarter-over-quarter.
- 5 funds opened new Nuvectis Pharma positions in Q2 2022 and 2 closed out, a net change of +3 holders.
- The largest Nuvectis Pharma buyer in Q2 2022 was Baldwin Wealth Partners, an estimated $1.5M added.
- The largest Nuvectis Pharma seller in Q2 2022 was Ronit Capital, an estimated $1.62M sold.
Based on aggregated 13F filings for Q2 2022.